Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.46 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.41 |
| ▸ | CHAT | P28329 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089041 | 0.99 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL30379563 | 0.88 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL26092659 | 0.86 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL30379384 | 0.86 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL30378872 | 0.86 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL26093100 | 0.85 | CHRM2 (0.52) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL26092766 | 0.85 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL30379184 | 0.84 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL30379896 | 0.84 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12533264 | 0.83 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419206-B1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA (ES) | 2025-09-17 | — | — | EP | claimed |
| US-20240415825-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2024-12-19 | — | — | US | claimed |
| EP-4419206-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundacio Institut de Bioenginyeria de Catalunya (ES) | 2024-08-28 | — | — | EP | claimed |
| CN-118475559-A | Compounds for malaria treatment | 加泰罗尼亚生物工程基金会研究所 | 2024-08-09 | — | — | CN | claimed |
| WO-2023067170-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) | 2023-04-27 | — | — | WO | claimed |
| EP-4419206-B1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA (ES) | 2025-09-17 | — | — | EP | disclosed |
| US-20240415825-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2024-12-19 | — | — | US | disclosed |
| EP-4419206-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | Fundacio Institut de Bioenginyeria de Catalunya (ES) | 2024-08-28 | — | — | EP | disclosed |
| CN-118475559-A | Compounds for malaria treatment | 加泰罗尼亚生物工程基金会研究所 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023067170-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415825-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | ABAT, GLS2, CPS1 | CHRM2 2286/4885CHRM4 3290/4885CHRM5 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.